PANCREATIC DISEASE ORIENTED GROUP
CHELSEA HOTEL, TORONTO, ON
ROOM: ROSSETTI
SATURDAY APRIL 28, 2018, 10:45 AM – 11:45 AM (1 HOUR)

CO-CHAIRS: DR. DAN RENOUF AND DR. ALICE WEI
SENIOR INVESTIGATOR: DR. CHRIS O’CALLAGHAN

CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:
- To interpret and address, through clinical and translational research, the disease burden associated with pancreatic malignancies in Canada.
- To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to pancreatic malignancies.
- To cite and analyze recent results of clinical studies conducted by or in collaboration with the Canadian Cancer Trials Group relevant to pancreatic malignancies.
- To interpret and apply new clinical trial methodologies in the field of clinical research in pancreatic malignancies.

10:45 am Setting Strategic Plan
Active/Recently Closed Trials for Update

11:05 am PA.6 (ACCORD 24): Randomized Multicenter Phase III Comparison of Adjuvant Chemotherapy with Gemcitabine versus a Combination of 5-Fluorouracil, Leucovorin, Irinotecan And Oxaliplatin (mFOLFIRINOX) in Patients with Resected Pancreatic Adenocarcinoma
Dr. J. Biagi

11:10 am PA.7: A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs. Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma
Dr. D. Renouf

11:20 am New Concepts in Development
Neoadjuvant FOLFIRINOX Trial concept
Dr. G. O’Kane

11:35 am COMPASS/PANGEN Sequencing Update
Dr. D. Renouf

11:40 am Intergroup Task Force Update
Dr. D. Renouf

11:45 am Meeting Adjourned